Two Phase 1b Studies Evaluating the Safety and Tolerability of BET Inhibitors, ABBV-744 and Mivebresib, as Monotherapies and in Combination with Ruxolitinib or Navitoclax in Patients with Myelofibrosis

被引：5
|
作者：
Mascarenhas, John
Saab, Rabih
Brackman, Deanna
Modi, Dimple A.
Abraham, Linu
Ward, James E.
Verstovsek, Srdan
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-137686
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 46 条
  • [21] A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma
    Kathryn E. Beckermann
    Amita Patnaik
    Ira Winer
    Winston Tan
    Babar Bashir
    Christos E. Kyriakopoulos
    Randy F. Sweis
    Marc Chamberlain
    Brian I. Rini
    Investigational New Drugs, 2024, 42 : 179 - 184
  • [22] CELEBRATE: A phase 1b study to evaluate the safety, tolerability and preliminary efficacy of the Combination of Encorafenib, Binimetinib and Palbociclib in patients with BRAF-mutant metastatic melanoma (The CELEBRATE study)
    Dixon-Douglas, Julia R.
    Soon, Jennifer
    Weppler, Alison
    Bailey, Chloe
    Parente, Phillip
    Shackleton, Mark
    Kee, Damien
    McArthur, Grant A.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 121 - 121
  • [23] A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma
    Beckermann, Kathryn E.
    Patnaik, Amita
    Winer, Ira
    Tan, Winston
    Bashir, Babar
    Kyriakopoulos, Christos E.
    Sweis, Randy F.
    Chamberlain, Marc
    Rini, Brian I.
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (02) : 179 - 184
  • [24] Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies
    Daruka Mahadevan
    Gregory Ryan Sutton
    Rafael Arteta-Bulos
    Chris J. Bowden
    Paul J. E. Miller
    Rachel Elizabeth Swart
    Mark S. Walker
    Paul Haluska
    Pamela N. Munster
    John Marshall
    Omid Hamid
    Razelle Kurzrock
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 467 - 473
  • [25] Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies
    Mahadevan, Daruka
    Sutton, Gregory Ryan
    Arteta-Bulos, Rafael
    Bowden, Chris J.
    Miller, Paul J. E.
    Swart, Rachel Elizabeth
    Walker, Mark S.
    Haluska, Paul
    Munster, Pamela N.
    Marshall, John
    Hamid, Omid
    Kurzrock, Razelle
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (03) : 467 - 473
  • [26] A randomized, double-blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis
    Klughammer, Barbara
    Piali, Luca
    Nica, Alexandra
    Nagel, Sandra
    Bailey, Lorna
    Jochum, Christoph
    Ignatenko, Stanislav
    Blauer, Angela
    Danilin, Sabrina
    Gulati, Pratiksha
    Hayward, Joanne
    Scepanovic, Petar
    Zhang, Jitao David
    Bhosale, Satish
    Chong, Chui Fung
    Christ, Andreas
    CLINICAL AND TRANSLATIONAL MEDICINE, 2023, 13 (11):
  • [27] Phase 1b randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of GLPG3667 in patients with moderate-to-severe plaque psoriasis
    Thaci, Diamant
    Molnar, Judit
    Timmis, Helen
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB92 - AB92
  • [28] A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan in patients with advanced or metastatic renal cell carcinoma (NCT06234605).
    Bupathi, Manojkumar
    Garmezy, Benjamin
    Mckay, Rana R.
    Ornstein, Moshe C.
    Figlin, Robert A.
    Picus, Joel
    Rank, Brian H.
    Barata, Pedro C.
    Hammers, Hans J.
    Hutson, Thomas E.
    Lam, Elaine T.
    Tykodi, Scott S.
    Zhao, Song
    Emamekhoo, Hamid
    Chisamore, Michael Jon
    Mattson, Paulette
    Holm, Megan
    Iglesias, Jose Luis
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : TPS609 - TPS609
  • [29] A phase 1b/2 study evaluating activity and tolerability of the BTK inhibitor ibrutinib in combination with ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases.
    Jaglowski, Samantha Mary
    Jones, Jeffrey Alan
    Flynn, Joseph M.
    Andritsos, Leslie A.
    Maddocks, Kami J.
    Woyach, Jennifer Ann
    Blum, Kristie A.
    Grever, Michael R.
    Geyer, Susan Michelle
    Heerema, Nyla A.
    Lozanski, Gerard
    Stefanos, Mona
    Hall, Nathan
    Nagar, Veena
    Munneke, Brian
    West, Jamie-Sue
    Neuenburg, Jutta
    James, Danelle Frances
    Johnson, Amy J.
    Byrd, John C.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREG™) in Patients with Advanced or Metastatic Renal Cell Carcinoma, NCT06234605
    McKay, Rana R.
    Garmezy, Ben
    Barata, Pedro
    Ornstein, Moshe
    Shah, Neil J.
    Hammers, Hans
    Hutson, Thomas E.
    Chisamore, Michael
    Karim, Dhamina
    Mattson, Paulette
    Lightcap, Eric
    Drees, Jeremy
    Harrison, Ben
    Holm, Megan
    Bose, Nandita
    Thomas, Cherry T.
    Motzer, Robert J.
    ONCOLOGIST, 2024, 29 : S13 - S13
12345